<DOC>
	<DOCNO>NCT02149875</DOCNO>
	<brief_summary>The investigator conduct randomized , double-blind , trial enrol 60 patient within 12 hour acute ischemic stroke ( AIS ) China . Patients randomly assign receive 10-day infusion dl-3-n-butylphthalide ( NBP ) cerebrolysin , placebo . National Institutes Health Stroke Scale ( NIHSS ) Barthel Index ( BI ) use evaluate efficacy patient AIS 11-day 21-day therapy . Adverse event also analyze among three group .</brief_summary>
	<brief_title>Dl-3-n-butylphthalide Cerebrolysin Treatment Acute Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>3-n-butylphthalide</mesh_term>
	<mesh_term>Cerebrolysin</mesh_term>
	<criteria>Acute ischemic stroke within 12 hour first time entry study National Institutes Health Stroke Scale ( NIHSS ) score 6 25 lacunar infarction cerebral hemorrhagic infarction epilepsy epileptic person history neurological diseases myocardial infarction , renal hepatic abnormality metabolic disease contraindication antiplatelet treatment</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Acute ischemic stroke</keyword>
	<keyword>Dl-3-n-butylphthalide</keyword>
	<keyword>Cerebrolysin</keyword>
</DOC>